Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13726117 | 0.86 | CHEK1 (0.49) | CHEK1SMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL19181014 | 0.85 | CHEK1 (0.48) | CHEK1SMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL8789657 | 0.85 | UBE2N (0.53) | CHEK1SMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL19181668 | 0.84 | CHEK1 (0.48) | CHEK1SMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL2593397 | 0.84 | ALDH1A1 (0.60) | CHEK1SMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL5673785 | 0.84 | ALDH1A1 (0.60) | CHEK1SMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL25734367 | 0.84 | ALDH1A1 (0.49) | CHEK1SMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL2593349 | 0.83 | CYP1A2 (0.50) | CHEK1MAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6588549 | 0.83 | CYP1A2 (0.47) | CHEK1SMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL5065594 | 0.83 | CYP1A2 (0.50) | CHEK1SMN1; SMN2MAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590516-B1 | ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| CN-117580836-A | Pyrimidine ring structure derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | disclosed |
| WO-2022268209-A1 | DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF | 四川汇宇制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| EP-3345907-B1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-25 | — | — | US | disclosed |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. , LTD. (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-3345907-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9920060-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | CHEK1 138/4885SMN1; SMN2 4250/4885MAPT 4023/4885 |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | ZYX, DPYD, ZFX | CHEK1 540/4885SMN1; SMN2 2489/4885MAPT 4754/4885 |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | CHEK1 278/4885SMN1; SMN2 4201/4885MAPT 4038/4885 |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | ERBB2, JAK2, ERBB4 | CHEK1 278/4885SMN1; SMN2 4201/4885MAPT 4038/4885 |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | ZYX, DPYD, ZFX | CHEK1 540/4885SMN1; SMN2 2489/4885MAPT 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.